AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04586244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCAGN02390
Description: INCAGN02390 will be administered via IV over 30 minutes (-5/+10 min) every 2 weeks.
Study NCT05138874 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trending Feedback
Description: Clinicians randomized to Trending Feedback will receive monthly feedback on the provider dashboard page.
Study NCT05138874 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Benchmark Peer Comparison Feedback
Description: Clinicians randomized to Benchmark Peer Comparison Feedback will receive monthly feedback on the provider dashboard page.
Study NCT05138874 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Private Commitment
Description: Clinicians assigned to the Private Commitment will be prompted in the provider dashboard to make a personal commitment to evidence-based use of antibiotics that will not be shared with their patients.
Study NCT05138874 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Public Commitment
Description: Clinicians assigned to Public Commitment will be prompted in the provider dashboard to make a commitment to evidence-based use of antibiotics that will be shared with their patients.
Study NCT05133193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: three kinds of antibiotics
Description: All patients were educated carefully about the medical instructions, including the duration of treatment, possible side effect, the necessity of completing the full 14-day course.
Study NCT05398393 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: oral Tenofovir Amibufenamide 25mg each day
Description: patients in three groups respectively take one tablet of Tenofovir Amibufenamide(25mg) every day
Study NCT05398393 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: lipid lowering drugs (e.g. Atorvastatin and amlodipine.)
Description: lipid lowering drugs, , patients in group B1 continue take lipid lowering drugs
Study NCT05852678 — intervention group
Intervention type: OTHER
Intervention: cohort
Description: The Cantabria Cohort will recruit 40,000-50,000 residents aged 40-69 years at baseline
Study NCT05603013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Vinorelbine Tartrate Oral
Study NCT05603013 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: hypofractionated radiotherapy
Study NCT05603013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1/PD-L1 inhibitor
Description: PD-1/PD-L1 inhibitor subcutaneous injection or intravenous injection
Study NCT05603013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: GM-CSF subcutaneous injection
Study NCT05603013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: IL-2 subcutaneous injection
Study NCT04836806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetirizine and Famotidine
Description: Participants will take 10 milligrams (mg) of cetirizine once a day and 20 mg of famotidine twice a day for 10 days (two pills in the morning and one in the evening).
Study NCT04836806 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will take placebos to match 10 mg of cetirizine once a day and 20 mg of famotidine twice a day for 10 days (two pills in the morning and one in the evening).
Study NCT06498544 — intervention group
Intervention type: OTHER
Intervention: Exposure to 3600 m
Description: Participants will travel to and stay for 2 nights at an altitude of 3600 m.
Study NCT05429034 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MIST paradigm
Description: Patients are exposed to psychosocial stress = receive mental arithmetic challenges, together with social evaluative threat components from the program and/or the investigator.
Study NCT05429034 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham paradigm
Description: Patients are not exposed to psychosocial stress = threat components from the program and/or the investigator are absent
Study NCT05877079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Menthol
Description: Patients will wear hand and foot wraps with 8% w/w menthol lotion (20 grams each) for 5 min. Patients will wear the wraps for 5 days per week. The total duration is 4 weeks.
Study NCT05877079 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will wear hand and foot wraps with lotion without menthol (20 grams each) for 5 min. Patients will wear the wraps for 5 days per week. The total duration is 4 weeks.
Study NCT06420414 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Participants engaged in a 15-minute HIIT session using the Facebook Oculus Quest 2 VR headset with the FitXR fitness game. The advanced level workout (High Speed) was chosen, where participants performed functional movements like squats, lunges, and trunk rotations while punching virtual targets. The VR environment provided a 10-second rest period between intervals and featured a virtual trainer's guidance.
Study NCT06420414 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional HIIT
Description: Participants followed a non-VR 15-minute HIIT programme designed to replicate the exercises and patterns seen in the FitXR game. The traditional exercises included squats, lunges, and punches, matching the VR programme's intensity and interval structure. Participants watched a pre-recorded video on a laptop, which guided them through the workout. The 10-second rest periods were also maintained for consistency.
Study NCT06241859 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dräger Infinity Delta series monitor (Dräger, Germany) with Covidien BIS LoC 2 channel module and BIS Quatro (4 electrodes) sensor (Covidien, Ireland)
Description: Dräger Infinity Delta series monitor (Dräger, Germany) with Covidien BIS LoC 2 channel module and BIS Quatro (4 electrodes) sensor (Covidien, Ireland) will be used to maintain a sedation depth between 80-90 value, which corresponds to light sedation definition.
Study NCT06241859 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Dräger Infinity Delta series monitor (Dräger, Germany) with Covidien BIS LoC 2 channel module and BIS Quatro (4 electrodes) sensor (Covidien, Ireland)
Description: Dräger Infinity Delta series monitor (Dräger, Germany) with Covidien BIS LoC 2 channel module and BIS Quatro (4 electrodes) sensor (Covidien, Ireland) will be used to monitor sedation depth.
Study NCT05956002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estraimod Immediate Release (IR)
Description: an immediate release tablet
Study NCT05956002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrasimod Mini Tab in water
Description: very small tablet mixed in water
Study NCT05956002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrasimod Mini Tab in chocolate pudding
Description: very small tablet mixed in chocolate pudding
Study NCT05956002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrasimod Mini Tab in yogurt
Description: Very small tablet mixed in yogurt
Study NCT05956002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrasimod Mini Tab in applesauce
Description: Very small tablet mixed in applesauce
Study NCT05119010 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Continuous ketogenic diet
Description: ARM A : continuous ketogenic diet
Study NCT05119010 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Discontinuous ketogenic diet
Description: ARM B : discontinuous ketogenic diet
Study NCT05119010 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: beta-hydroxybutyrate (BHB) supplementation
Description: ARM C : BHB supplementation
Study NCT05010733 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total hip arthroplasty using the Exeter V40 cemented femoral stem
Description: Consists of applying a cement layer of at least 2 millimeters surrounding an undersized prosthetic stem, so that this layer of cement fits between the femoral medullary canal and the prosthetic's femoral stem.
Study NCT05010733 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total hip arthroplasty using the Müller Straight Stem
Description: Consists of applying a thin layer of cement, so that the prosthetic's femoral stem fills as much as possible the femoral medullary canal.
Study NCT05703035 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standby while firing staple
Description: VOLUNTEER PATIENTS WHO ACCEPT THE SURGERY WILL HAVE TISSUE CLOSURE AND CUTTING WITH STAPLER IN AVERAGE 30 MINUTES DURING THE SURGERY AND THE PATIENT WILL BE FOLLOWED FOR 30 DAYS.
Study NCT05178771 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet rich fibrin
Description: 1. Intravenous blood (obtained by venipuncture of the antecubital vein) will be collected in two 10-mL sterile tubes without any anticoagulants and will be immediately centrifuged at 3,000 revolutions (400 × g) per minute for 10 minutes.~2. A structured fibrin clot in the middle of the tube, just between the red corpuscles (RBCs) at the bottom and the acellular plasma at the top, will be separated from the RBCs using sterile tweezers and scissors and transferred on a sterile PRF box.~3. The PRF will be then brought to a thickness of 1 mm by gently compressing in PRF box. Standardized PRF pieces will be obtained by measuring by a periodontal probe and cutting into 3 × 5 mm dimensions.~4. The PRF pieces will be inserted into the periodontal pockets by filling the pockets from the base up to the gingival margin. A modified gingivectomy knife, of which the tip is made blunt, will be used.~The PRF volume will be calculated by recording how many pieces will be inserted.
Study NCT04242329 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical metastasectomy
Description: Surgical removal of metastases aimed at R0 resection.
Study NCT05175209 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: EMG
Description: Electromyelography
Study NCT05206487 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Polydextrose
Description: PDX will be started 2 weeks before TIPS and taken daily for a 6 month period after TIPS.
Study NCT04242329 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immunotherapy
Description: Continued PD1-inhibitor treatment according to current treatment standards.
Study NCT06255964 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: IAP0971
Description: Induction period (6 weeks): IAP0971 single drug bladder infusion, once a week;Maintenance period: IAP0971 single drug bladder infusion, performed at 3, 6, 12, 18, and 24 months, once a week, for 3 consecutive times
Study NCT06255964 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: IAP0971＋BCG
Description: Induction period (6 weeks): IAP0971 combined with BCG,Bladder perfusion, once a week;Maintenance period: IAP0971 combined with BCG bladder perfusion,Maintain at months 3, 6, 12, 18, and 24Perfusion, once a week, three times in a row.
Study NCT06255964 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: IAP0971＋BCG
Description: Induction period (6 weeks): IAP0971 combined with BCG,Bladder perfusion, once a week;Maintenance period: IAP0971 combined with BCG bladder irrigationNote, progress at months 3, 6, 12, 18, and 24Perform maintenance perfusion once a week, three times in a row.
Study NCT05014893 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: multi-modal targeted intervention (e.g., cognitive training, exercise, games)
Description: The Intervention group will be given recommended interventions tailored to individuals based on their risks (e.g., physical exercise programs, cognitive training, dietary advice, control of blood pressure and cholesterol, healthy diet, control obesity, stop smoking,reduce alcohol excess)
Study NCT05990036 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sports vision enhancement training curriculum
Description: A curriculum of 8 sports vision training procedures applied during women's collegiate softball team training. The training protocol consists of once weekly training sessions, 45 minutes in duration.
Study NCT06324279 — intervention group
Intervention type: DEVICE
Intervention: Transvaginal ultrasound
Description: Transvaginal ultrasound will be used to see the presence of cervical sliding sign
Study NCT06324279 — intervention group
Intervention type: DRUG
Intervention: Misoprostol 200mcg Tab
Description: Induction of labor by misoprostol
Study NCT05754697 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instrument assisted soft tissue mobilization in addition to traditional treatment
Description: The treatment protocol will be two sessions will be given per week for 4 weeks.
Study NCT05754697 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positional release technique in addition to traditional treatment
Description: The treatment protocol will be two sessions will be given per week for 4 weeks.
Study NCT04834648 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured Counseling
Description: Structured Counseling, which includes A. Counseling is done by a trained counselor~B. Telephonic Follow up:~C. Development of Fast Track system at the Base Hospital. D. Provide Health Education Material to all Diabetic Patients. E. Referral communication and feedback between referring and referral facility.
Study NCT06516861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate 20 MG/ML
Description: Administered intravenously with a dose of 30 mg/kg
Study NCT05035888 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: An initial prophylactic bolus dose of phenylephrine (37.5μg) simultaneous with spinal anesthesia. If the patient did not respond adequately to the current dose (SBP decreased to \< 80% of baseline), the dose was considered to have failed and the subsequent dose for the following patient was increased to the next higher dose level. The dose administered to subsequent patients varied by increments or decrements of 12.5 μg according to the responses of previous patients according to the up-down sequential allocation.
Study NCT05035888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: An initial prophylactic bolus dose of norepinephrine (3μg) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 1 μg according to the responses of previous patients according to the up-down sequential allocation.
Study NCT05464602 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention group Lavender
Description: This group received inhalation aromatherapy 2 drops of lavender oil from aromastone for a total of 3 days, one day before the operation, the day of the operation and the first day after the operation.
Study NCT05464602 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention group Geranium
Description: This group received inhalation aromatherapy 2 drops of geranium oil from aromastone for a total of 3 days, one day before the operation, the day of the operation and the first day after the operation.
Study NCT06547736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A2102 or/and HRS-4642
Description: Drug: SHR-A2102 SHR-A2102 will be administrated per dose level in which the patients are assigned.~Drug: HRS-4642 HRS-4642 will be administrated per dose level in which the patients are assigned.
Study NCT06547736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1904 or/and HRS-4642
Description: Drug: SHR-A1904 SHR-A1904 will be administrated per dose level in which the patients are assigned.~Drug: HRS-4642 HRS-4642 will be administrated per dose level in which the patients are assigned.
Study NCT06547736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811 or/and HRS-4642
Description: Drug: SHR-A1811 SHR-A1811 will be administrated per dose level in which the patients are assigned.~Drug: HRS-4642 HRS-4642 will be administrated per dose level in which the patients are assigned.
Study NCT05217173 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telerehabilitation
Description: It will start within the first 72 hours of having started with the condition (ankle sprain); They will receive a rehabilitation program using a mobile application (through a digital platform course), which will contain previously recorded videos with exercises that will serve as a guide for rehabilitation activities. The duration of the program will be 30 minutes a day, 5 days a week for 4 weeks
Study NCT04764526 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protein-enriched ice cream
Description: Offering two protein-enriched ice creams
Study NCT04767711 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus reuteri ATCC PTA 6475 (L. reuteri 6475)
Description: L.reuteri with cholecalciferol compared to cholecalciferol only.
Study NCT04767711 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Oral glucocorticoid 25 mg daily for 7 days.
Study NCT04767711 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisolone
Description: Oral glucocorticoid 25 mg daily for 7 days.
Study NCT05201651 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine Monohydrate
Description: Participants will orally consume creatine (20 grams in 4×5-gram servings for seven days), followed by 3-g/day during training days. This 3-g/day dosage has been shown to maintain cellular creatine levels.
Study NCT05201651 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin Placebo
Description: Participants will orally consume maltodextrin placebo (20 grams in 4×5-gram servings for seven days), followed by 3-g/day during training days.
Study NCT06464770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine Gluconate
Description: Test Group: the participant's shoulder skin will be treated by the study team with the standard chlorhexidine wash at lower pressure (similar to a gentle wipe) for 30 seconds Control Group: the participant's shoulder skin will be treated by the study team with the standard chlorhexidine wash at higher pressure (similar to a massage) for 30 seconds
Study NCT06518915 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: baroloop system
Description: Participants will have the baroloop device implanted for selective stimulation of the vagus nerve.
Study NCT05754697 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional treatment
Description: The treatment protocol will be two sessions will be given per week for 4 weeks.
Study NCT05186740 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ProVee Urethral Expander System
Description: ProVee Expander is placed in prostatic urethra to relieve obstruction due to BPH.
Study NCT05186740 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ProVee Urethral Expander System
Description: ProVee Expander is placed in prostatic urethra to relieve obstruction due to BPH.
Study NCT05186740 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Urethral Access Sheath
Description: The Urethral Access Sheath is introduced into the prostatic urethra to simulate the placement of the ProVee Expander.
Study NCT06174675 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: combined bilateral infraorbital and infratrochlear nerve blocks
Description: Filling the block labelled syringe with 8 mL of bupivacaine 0.25%. Starting with Infraorbital nerve block using an extraoral approach.Inserting a 25-gauge needle laterally to the ipsilateral nostril after palpating the infraorbital ridge to locate the infraorbital foramen. Positioning of the index finger of the non-dominant hand above the infraorbital foramen and advancing the needle feeling it beneath the finger to avoid globe penetration injury. Injecting 3 mL of the study solution slowly after confirming negative aspiration of blood and taking care not to inject into the foramen itself.~Shifting to infratrochlear nerve block by inserting the needle 1 cm above the inner canthus targeting the junction of the orbit and the nasal bone. Injecting 1mL of the study solution after confirming negative aspiration of blood.~Performing contralateral nerve block in the same manner. Applying pressure to four injection points for one minute to prevent hematoma.
Study NCT05361174 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IOV-4001
Description: A tumor sample is resected from each participant and cultured ex-vivo to manufacture IOV-4001. After lymphodepleting chemotherapy including cyclophosphamide and fludarabine, participant is infused with IOV-4001, and followed by IL-2.
Study NCT05279664 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning (RIC) + Standard of Care for NEC
Description: RIC will consist of 4 cycles of limb ischemia (5 min) followed by reperfusion (5 min), repeated on two consecutive days. An appropriately sized blood pressure cuff (covering 2/3 of the distance between the shoulder and the elbow) will be applied by a trained research fellow or nurse to an arm (or leg if the arm is not available because of medical reasons such as central line insertion). The systolic blood pressure will be measured before the first RIC cycle using a different cuff of same size connected to a monitor. During ischemia time, the cuff will be inflated to a pressure of 15 mmHg above the child's systolic pressure. Neonates in this arm will continue to receive standard of care for NEC.
Study NCT05279664 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard of Care for NEC
Description: Neonates in this arm (i.e. the control arm) will receive standard of care for NEC.